Welcome to our dedicated page for Ufp Technologies SEC filings (Ticker: UFPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The UFP Technologies, Inc. (UFPT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed issuer. UFP Technologies is a contract development and manufacturing organization specializing in single-use and single-patient medical devices, and its filings offer detailed insight into its operations, financial performance, and risk profile in the medical device supply chain.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which include information on net sales, gross profit, operating income, net income, segment performance, and non-GAAP measures such as organic sales growth, adjusted operating income, adjusted net income, and adjusted EBITDA. These filings also contain management’s discussion and analysis and risk factor sections that elaborate on topics referenced in the company’s press releases, including customer concentration, acquisition integration, supply chain and labor considerations, and regulatory and market risks.
Stock Titan also surfaces current reports on Form 8-K, where UFP Technologies furnishes earnings press releases and investor presentation materials under items such as Results of Operations and Financial Condition and Regulation FD Disclosure. These 8-Ks link the narrative in press releases to the formal SEC record and often include exhibits with detailed financial tables and reconciliations.
In addition to core periodic and current reports, users can monitor other SEC documents related to UFP Technologies, including any proxy materials and insider transaction reports when available. Stock Titan enhances these filings with AI-powered summaries that explain key sections in plain language, highlight important changes from prior periods, and help readers quickly locate information on topics such as MedTech versus non-medical sales, acquisition impacts, and capital structure.
UFP Technologies reported solid first-quarter 2026 results with modest growth and continued strength in its medical business. Net sales rose to $154.2 million from $148.1 million, driven by 5.9% higher sales to medical customers, especially in robotic surgery, patient surfaces, and interventional and surgical products. Non-medical revenue declined 15%.
Gross margin edged up to 28.8%, supported by efficiencies in robotic surgery. Net income increased slightly to $17.5 million, or $2.24 diluted EPS, compared with $17.2 million and $2.21 a year earlier. Two major customers accounted for 24.8% and 22.1% of net sales, underscoring meaningful customer concentration.
Operating cash flow was $3.2 million, as higher receivables and inventory absorbed cash despite strong earnings. Cash stood at $20.0 million, and total debt under the company’s $275 million credit facility was $137.6 million at a roughly 5.0% average interest rate, with all covenants met.
Management highlighted reduced tariff impacts and expects future refunds via vendor credits after recent U.S. court decisions. A February 2026 cyber incident did not materially affect systems or results, though the company cautions that future cybersecurity issues could pose risks.
UFP Technologies reported modestly higher results for the first quarter ended March 31, 2026. Net sales reached $154.2 million, up 4.1% from $148.1 million a year earlier, while net income rose 1.8% to $17.5 million.
GAAP diluted EPS was $2.24 and adjusted diluted EPS was $2.48, compared with $2.21 and $2.47 in 2025. Medical market sales grew 5.9% to $143.4 million, but non-medical sales fell 15.0% to $10.8 million, reflecting the company’s focus on MedTech.
Gross margin edged up to 28.8%, while SG&A increased to $21.0 million, or 13.6% of sales. Operating income was $23.4 million, and adjusted EBITDA improved to $31.0 million. Management highlighted growth in robotic surgery and patient support segments and plans to add two new facilities in the Dominican Republic to meet forecasted demand.
UFP Technologies, Inc. has called a virtual annual meeting for June 4, 2026 at 10:00 a.m. Eastern, where shareholders can vote online using a 16‑digit control number. The agenda includes electing seven directors for one‑year terms, an advisory vote on executive pay, and ratifying Grant Thornton LLP as independent auditor for 2026.
The proxy details a planned leadership transition: long‑time CEO R. Jeffrey Bailly will retire as Chief Executive Officer effective June 4, 2026 and, if re‑elected, become Executive Chairman, while President Mitchell C. Rock will become Chief Executive Officer. As of April 10, 2026, 7,736,939 shares of common stock were outstanding and entitled to one vote per share. The filing also highlights majority‑independent board and committees, stock ownership guidelines, an executive compensation clawback policy, prohibition on hedging and pledging company stock, and a pay program that combines salary, performance‑based cash bonuses, and time‑ and performance‑based restricted stock units tied to adjusted operating income targets.
Congress Asset Management filed a Schedule 13G reporting beneficial ownership of 5.4% of UFP Technologies Inc. common stock as of 03/31/2026. The filing shows 416,762 shares held with sole voting and dispositive power.
UFP Technologies Inc ownership filing shows The Vanguard Group reporting no beneficial ownership of Common Stock following an internal realignment.
The filing states Vanguard disaggregated certain subsidiaries and business divisions and will report holdings separately in reliance on SEC Release No. 34-39538; the reported amount beneficially owned is 0 shares (0%).
UFP Technologies director Thomas Oberdorf exercised stock options to acquire 2,864 common shares. He exercised options at an exercise price of $22.02 per share, converting them into the same number of common shares. Following the transaction, he directly holds 12,417 shares of UFP Technologies common stock, and this option grant is fully exercised with no remaining derivative position reported.
UFP Technologies Vice President Jason Holt reported a tax-related share disposition. On March 2, 2026, 478 shares of common stock were withheld at a price of $204.30 per share to cover tax liabilities arising from stock unit awards granted in 2023, 2024 and 2025 that vested on that date. After this withholding, Holt directly owned 8,978 shares of UFP Technologies common stock.
UFP Technologies Senior Vice President Christopher P. Litterio reported a tax‑related share disposition. On March 2, 2026, 815 shares of UFP Technologies common stock at a reference price of $204.30 per share were withheld to cover tax liabilities on stock unit awards granted in 2023, 2024 and 2025 that vested that day. After this tax-withholding disposition, he directly owned 11,977 shares of common stock.
UFP Technologies President Mitchell Rock reported a Form 4 showing a tax-related share disposition. On stock units that vested on March 2, 2026, 2,513 shares of common stock were withheld at $204.30 per share to cover tax liabilities, rather than being sold on the open market. After this withholding, Rock directly owns 36,220 shares of UFP Technologies common stock.